Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 7Withdrawn 1Unknown 1Suspended 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Neoplasms 46Breast Neoplasms 46Colorectal Neoplasms 27Prostatic Neoplasms 26Carcinoma, Non-Small-Cell Lung 21Leukemia, Myeloid, Acute 20Glioblastoma 19Melanoma 17Lung Neoplasms 17Pancreatic Neoplasms 16Neoplasm Metastasis 16Glioma 14Stomach Neoplasms 13Ovarian Neoplasms 13Brain Neoplasms 13Carcinoma, Hepatocellular 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Myelodysplastic Syndromes 11Triple Negative Breast Neoplasms 10Multiple Myeloma 10Head and Neck Neoplasms 10Carcinoma, Renal Cell 10Lymphoma 9Uterine Cervical Neoplasms 7Sarcoma 7Rectal Neoplasms 7Leukemia 7Hematologic Neoplasms 7Esophageal Neoplasms 7Colonic Neoplasms 7

Interventions

venetoclax 1regorafenib 1Specimen Handling 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × GATA2 Deficiency × Clear all
NCT06454409 2025-11-19

Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

City of Hope Medical Center

Phase 1 Suspended
20 enrolled
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡